Roche Diagnostics MD bids farewell after two-decades, leading the organisation to new heights of success

Diagnostics & MedTech News: The Managing Director of Roche Diagnostics Australia, Allison Rossiter, has announced her resignation, effective September 2024. This significant development concludes Rossiter’s notable 22-year tenure within the organisation. Throughout her leadership journey, Rossiter has played a pivotal role in steering Roche Diagnostics towards growth and success, leaving an indelible mark on its trajectory.

Since joining Roche UK in 2002, Rossiter has navigated a remarkable career path. Reflecting on her journey, she told Health Industry Hub, “I never imagined that I would have the good fortune to have such a life changing career – working with some of the most talented people in the industry, making an impact to lives and travelling the world. It really has been a dream come true, and one that I am very grateful for.”

Contemplating her time at Roche Diagnostics Australia over the past five years, Rossiter expressed deep appreciation for the organisation’s transformation and accomplishments.

“A career highlight for me has been working here in Australia over the past 5 years. Our organisation is unrecognisable from where we started in 2019. We have gone from strength to strength. Firstly recognising that we needed to change our culture, customer and patient centricity, and our focus – then actually having the courage to make the vision a reality, despite the many challenges that we faced.  

“All that on top of a global pandemic where we played a key role in helping to keep Australian’s safe through COVID. Today we are a totally different company, and the results speak for themselves,” she explained.

Driven by a desire for personal growth and familial considerations, Rossiter has chosen to embark on a new chapter that promises to challenge and inspire in equal measure.

“Always looking to learn and become a better version of myself I have decided to take on a new challenge. I wasn’t looking to change roles just yet but I was offered an opportunity that will allow me to stay in Australia so my children can graduate high school, and will challenge me enormously, experiencing situations that I would never encounter at Roche,” she told Health Industry Hub.

Throughout the transition period leading up to September, Rossiter remains committed to maintaining the organisation’s momentum and ensuring continuity in operations.

“While I will miss my Roche team enormously – not to mention our awesome kick off meetings and disco dancing extravaganzas – I am incredibly proud of what we have created together, and I am in no doubt that the team at Roche Diagnostics will continue to lead the way and ensure better outcomes for everyone in Australia.

“Between now and September, it’s business as usual. I am fully committed to executing on our priorities.”

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.